Can Fite Biopharma Ltd.-ADRCANF
13F holders, Q1 2026 (March 31)14holders +13
5new positions
1sold out
1famous investor
$3.10avg. 13F price*
At the end of Q1 2026, 14 institutions reported holding Can Fite Biopharma Ltd.-ADR (CANF) in their 13F filings, up 13 from Q4 2025. 5 opened new positions and 1 sold out. The largest holders were Sabby Management, LLC ($132K), Citadel Advisors ($106K) and Rhumbline Advisers ($65K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Can Fite Biopharma Ltd.-ADR
- CUSIP
- 13471N409
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $355K |
| Exits | 1 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 122,401 shares bought and 1,352 shares sold, net +121,049 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Sabby Management, LLC | 2.49% | New | 42,559 | $132K |
| Citadel Advisors | 0.00% | New | 34,150 | $106K |
| Rhumbline Advisers | 0.00% | Add +48.4% | 20,908 | $65K |
| HRT Financial LP | 0.00% | New | 19,383 | $60K |
| Virtu Financial LLC | 0.00% | New | 12,908 | $40K |
| Citigroup Inc. | 0.00% | New | 5,482 | $17K |
| UBS Group AG | 0.00% | Add +105.5% | 2,152 | $7K |
| Osaic Holdings, Inc. | 0.00% | Reduce -75.0% | 450 | $1K |
| Fifth Third Bancorp | 0.00% | No change | 150 | $465 |
| Wells Fargo & Company | 0.00% | No change | 125 | $388 |
| Activest Wealth Management | 0.00% | No change | 10 | $31 |
| Morgan Stanley | 0.00% | Reduce -39.4% | 1 | $3 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 1 | $3 |
| Avion Wealth | 0.00% | No change | 5 | $0 |
"% of holder's portfolio" is CANF's weight in each manager's 13F, not the share of Can Fite Biopharma Ltd.-ADR the manager owns.